Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial

• Published in: Current controlled trials in cardiovascular medicine 2022-01, Vol.23 (1), p.37-9, Article 37
• Main Authors: Yang, Xiaochen, Liu, Lanping, Xiong, Xingjiang, Zhang, Yun, Liu, Yongmei, Li, Hongzheng, Yao, Kuiwu, Wang, Jie
• Format: Article
• Language: English
• Subjects: Antihypertensives; Blood Pressure; Care and treatment; China; Chinese medicine; Clinical medicine; Clinical trials; Diagnosis; Double-Blind Method; Double-blind studies; Glucose; Humans; Hypertension; Hypertension - diagnosis; Hypertension - drug therapy; Insulin resistance; Lipids; Metabolism; Middle age; Patients; Pharmacogenetics; Randomized Controlled Trials as Topic; Risk factors; Study Protocol; Treatment Outcome
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-022-05999-2

Hypertension is one of the most important risk factors for cardiovascular disease, and its control rates remain low worldwide. The most effective strategy is that patients with hypertension should be diagnosed and treated early. Preliminary studies showed that the Bushen Jiangya granule (BSJY) could suppress ventricular hypertrophy and inflammatory responses, lower blood pressure, and protect the target organs of hypertension. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of BSJY in patients with low-to-medium risk hypertension. This trial is a one-center, randomized, double-blind, placebo-controlled study. A total of 260 participants will be randomized in a 1:1 ratio to an experimental group (BSJY plus amlodipine) and a control group (placebo plus amlodipine). The trial cycle will last 8 weeks. The primary outcome is the change in 24-h average systolic and diastolic blood pressure. The secondary outcomes include heart rate variability, pharmacogenomic evaluation, improvement in TCM syndrome, and serum pro-inflammatory/anti-inflammatory cytokines between the two groups. The safety of medication will also be evaluated. All the data will be recorded in electronic case report forms and analyzed by SPSS V.22.0. This study has been approved by the Research Ethics Committee of Guang'anmen Hospital, China Academy of Chinese Medical Sciences in Beijing, China (No. 2019-186-KY-01). The participants are volunteers, understand the process of this trial, and sign an informed consent. The results of this study will be disseminated to the public through peer-reviewed journals and academic conferences. We hypothesize that patients with low-to-medium-risk hypertension will benefit from BSJY. If successful, this study will provide evidence-based recommendations for clinicians. Chinese Clinical Trial Registry ChiMCTR1900002876. Registered in November 2019.